Last reviewed · How we verify
Cannabidiol 400
Cannabidiol 400 is a cannabinoid receptor agonist Small molecule drug developed by Hurd,Yasmin, Ph.D.. It is currently in Phase 2 development for Seizure disorders, Multiple sclerosis. Also known as: CBD.
Cannabidiol 400 acts as a cannabinoid receptor agonist, modulating the endocannabinoid system to exert therapeutic effects.
Cannabidiol 400 acts as a cannabinoid receptor agonist, modulating the endocannabinoid system to exert therapeutic effects. Used for Seizure disorders, Multiple sclerosis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cannabidiol 400 |
|---|---|
| Also known as | CBD |
| Sponsor | Hurd,Yasmin, Ph.D. |
| Drug class | cannabinoid receptor agonist |
| Target | CB1 and CB2 receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Cannabidiol 400 binds to cannabinoid receptors in the body, influencing various physiological processes, including pain perception, inflammation, and mood regulation. This interaction can lead to therapeutic benefits in conditions such as epilepsy and multiple sclerosis. However, the exact mechanisms underlying cannabidiol's effects are still being researched and understood.
Approved indications
- Seizure disorders
- Multiple sclerosis
Common side effects
- Drowsiness
- Diarrhea
- Fatigue
Key clinical trials
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- Cannabidiol in Opioid Use Disorder and Chronic Pain (EARLY_PHASE1)
- Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI (PHASE2)
- Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (PHASE3)
- Study of Cannabidiol and Neuroimaging on Stress (PHASE1, PHASE2)
- Adjunctive Cannabidiol for Recovery From Opioid Study (PHASE3)
- Investigation of the Pharmacokinetic Profile of CBD - Phase 1 ANANDA (PHASE1)
- Effects of Cannabidiol on Stress and Nicotine Withdrawal (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabidiol 400 CI brief — competitive landscape report
- Cannabidiol 400 updates RSS · CI watch RSS
- Hurd,Yasmin, Ph.D. portfolio CI
Frequently asked questions about Cannabidiol 400
What is Cannabidiol 400?
How does Cannabidiol 400 work?
What is Cannabidiol 400 used for?
Who makes Cannabidiol 400?
Is Cannabidiol 400 also known as anything else?
What drug class is Cannabidiol 400 in?
What development phase is Cannabidiol 400 in?
What are the side effects of Cannabidiol 400?
What does Cannabidiol 400 target?
Related
- Drug class: All cannabinoid receptor agonist drugs
- Target: All drugs targeting CB1 and CB2 receptors
- Manufacturer: Hurd,Yasmin, Ph.D. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Seizure disorders
- Indication: Drugs for Multiple sclerosis
- Also known as: CBD
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing